Exploring the Diversity and Specificity of Secondary Biosynthetic Potential in Rhodococcus
Marine Drugs · 2024
DOI: 10.3390/md22090409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2024. Verfasst von Gang-Ao Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang Key Laboratory of G…. Hauptthemen laut MEDLINE: Rhodococcus, Multigene Family, Phylogeny, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Programs of China, National Key Research and Development Programs, Fundamental Research Funds for the Provincial Universities of Zhejiang.
Abstract (Originalsprache)
The actinomycete genus Rhodococcus is known for its diverse biosynthetic enzymes, with potential in pollutant degradation, chemical biocatalysis, and natural product exploration. Comparative genomics have analyzed the distribution patterns of non-ribosomal peptide synthetases (NRPSs) in Rhodococcus. The diversity and specificity of its secondary metabolism offer valuable insights for exploring natural products, yet remain understudied. In the present study, we analyzed the distribution patterns of biosynthetic gene clusters (BGCs) in the most comprehensive Rhodococcus genome data to date. The results show that 86.5% of the gene cluster families (GCFs) are only distributed in a specific phylogenomic-clade of Rhodococcus, with the most predominant types of gene clusters being NRPS and ribosomally synthesized and post-translationally modified peptides (RiPPs). In-depth mining of RiPP gene clusters revealed that Rhodococcus encodes many clade-specific novel RiPPs, with thirteen core peptides showing antibacterial potential. High-throughput elicitor screening (HiTES) and non-targeted metabolomics revealed that a marine-derived Rhodococcus strain produces a large number of new aurachin-like compounds when exposed to specific elicitors. The present study highlights the diversity and specificity of secondary biosynthetic potential in Rhodococcus, and provides valuable information for the targeted exploration of novel natural products from Rhodococcus, especially for phylogenomic-clade-specific metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang Key Laboratory of Green, Low-Carbon, and Efficient Development of Marine Fishery Resource…
- Binjiang Institute of Artificial Intelligence, Zhejiang University of Technology (ZJUT), Hangzhou 310051, China.
ORCID-Profile: Jian-Wei Chen, Hong Wang, Bin Wei
Förderung
- National Key Research and Development Programs of China
- National Key Research and Development Programs
- Fundamental Research Funds for the Provincial Universities of Zhejiang
- National Natural Science Foundation of China
Zitieren
APA
Hu, G. A., Song, Y., Liu, S. Y., Yu, W. C., Yu, Y. L., Chen, J. W., Wang, H., & Wei, B. (2024). Exploring the Diversity and Specificity of Secondary Biosynthetic Potential in Rhodococcus. Marine Drugs. https://doi.org/10.3390/md22090409
Vancouver
Hu GA, Song Y, Liu SY, Yu WC, Yu YL, Chen JW, et al. Exploring the Diversity and Specificity of Secondary Biosynthetic Potential in Rhodococcus. Marine Drugs. 2024. doi:10.3390/md22090409
BibTeX
@article{Hu2024,
author = {Hu, Gang-Ao and Song, Yue and Liu, Shi-Yi and Yu, Wen-Chao and Yu, Yan-Lei and Chen, Jian-Wei and Wang, Hong and Wei, Bin},
title = {Exploring the Diversity and Specificity of Secondary Biosynthetic Potential in Rhodococcus},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22090409}
}
EUVIMED